Two oral GLP-1 medications are now FDA-approved specifically for weight loss — the Wegovy pill (oral semaglutide 25 mg, approved December 2025) and Foundayo (orforglipron, approved April 2026). A third oral GLP-1, Rybelsus, remains approved only for type 2 diabetes but is still sometimes prescribed off-label for weight management.
Whether your insurance covers any of these depends on your plan type, your diagnosis, and increasingly on your employer's benefit design decisions. Here's the landscape as it stands in mid-2026.
The Core Problem: Indication Drives Coverage
Insurance coverage follows the FDA-approved indication, not the molecule. Semaglutide — the same active ingredient — gets covered under one brand name and denied under another, depending on what it was prescribed for.
Ozempic (semaglutide injection for type 2 diabetes) is widely covered on most commercial and Medicare formularies. Wegovy (semaglutide injection for obesity) is excluded from many plans. The Wegovy pill, despite being the same molecule in a different format, faces the same obesity-indication exclusions that the Wegovy injection does.
This is the single biggest factor determining whether you'll get coverage for an oral GLP-1: does your plan cover anti-obesity medications at all?
Coverage by Insurance Type
| Plan Type | Wegovy Pill | Foundayo | Rybelsus (Off-Label WL) |
|---|---|---|---|
| Commercial (employer) | Varies widely — depends on whether employer includes anti-obesity meds | Too new — most formularies haven't added it yet as of mid-2026 | Rarely covered for weight loss (off-label) |
| Medicare Part D | Bridge program — covered via Medicare GLP-1 Bridge starting July 2026 ($50 copay) | Bridge program — all formulations eligible starting July 2026 | Covered when prescribed for type 2 diabetes |
| Medicaid | 13 states cover GLP-1s for weight loss; 3 states eliminated coverage Jan 2026 | State-dependent — likely mirrors Medicaid GLP-1 policies | State-dependent for diabetes indication |
| Tricare | May be covered with prior authorization and documented failed lifestyle intervention | TBD — Tricare formulary status unclear as of May 2026 | Not covered for off-label weight loss |
| ACA Marketplace | Plan-dependent — most Marketplace plans exclude obesity drugs | Plan-dependent | Rarely covered off-label |
Commercial Insurance: The Biggest Variable
Employer-sponsored plans make up the largest share of insured Americans, and coverage for weight loss medications within these plans is inconsistent and — for many patients — getting worse.
According to 2025 survey data, about 36% of employers said they covered GLP-1 medications for weight loss, up slightly from 34% the year before. But the share of employers who said they explicitly didn't offer coverage also grew, from 52% to 57%. And going into 2026, some major pharmacy benefit managers have been reshuffling formularies in ways that dropped coverage for millions of patients.
If your employer plan does cover anti-obesity medications, the Wegovy pill will likely be covered under the same terms as the Wegovy injection — same prior authorization requirements, same formulary tier, same cost-sharing. Foundayo coverage through commercial plans is still emerging; most employer formularies haven't made formal decisions on it yet given how recently it was approved.
How to Check Your Coverage
Steps to verify your commercial plan coverage:
- Log into your insurer's member portal (UnitedHealthcare, Aetna, Cigna, BCBS, etc.)
- Use the drug lookup/formulary tool — search by brand name (Wegovy, Foundayo)
- Note the tier, prior authorization requirements, and any step therapy flags
- Check your plan's Summary of Benefits for "anti-obesity medications" or "weight loss drugs" exclusions
- Call the number on your insurance card and ask specifically whether anti-obesity medications are a covered benefit
Medicare: The GLP-1 Bridge Program
Until recently, Medicare Part D was statutorily prohibited from covering medications prescribed for weight loss. The Treat and Reduce Obesity Act (TROA) removed that exclusion, and individual Part D plans are now permitted — but not required — to cover anti-obesity medications.
To provide broader access while long-term coverage policies are developed, CMS created the Medicare GLP-1 Bridge program, which runs from July 1, 2026 through December 31, 2027. The Bridge program covers all formulations of Wegovy (including the oral pill), all formulations of Foundayo, and the Zepbound KwikPen at a $50 monthly copay for eligible beneficiaries.
Eligibility requires enrollment in a Part D plan (standalone PDP or MA-PD plan), a prior authorization submitted by your provider, and a prescription for obesity — not a condition already coverable under standard Part D (such as Wegovy for cardiovascular risk reduction, which should go through normal Part D formulary channels).
Self-Pay Pricing: When Insurance Isn't an Option
If your insurance doesn't cover oral GLP-1 medications — or if you're uninsured — manufacturer pricing programs and telehealth subscription models provide alternative access paths.
$299/mo at 25 mg maintenance
Via NovoCare or participating telehealth
Via LillyDirect or participating telehealth
Higher dose pricing may vary
Foundayo: check LillyDirect for current offers
Novo Nordisk launched a multi-month subscription program for Wegovy in March 2026, offering fixed monthly pricing through select telehealth providers including Ro, Hims & Hers, Sesame, WeightWatchers, and LifeMD. These programs include 3-, 6-, or 12-month subscription options. The 4 mg dose introductory price of $149/month is available through August 2026, after which it rises to $199/month.
Does the Pill Format Affect Coverage Differently Than the Injection?
In most cases, no. Coverage decisions are driven by the indication (obesity vs. diabetes), not the delivery format. If your plan covers Wegovy injection, it will generally cover the Wegovy pill under the same terms. If your plan excludes anti-obesity medications, it will exclude both the pill and the injection.
There are a few edge cases. Some plans may require step therapy — trying the pill before the injection, or vice versa. Some pharmacy benefit managers may place the pill and injection on different formulary tiers with different copays. And switching from injection to pill may require a new prior authorization, even if you were already approved for the injectable version.
For patients switching between formulations, insurance may require documentation that the switch is medically appropriate — not just a convenience preference.
What About Compounded Oral GLP-1s?
Compounded oral semaglutide (sublingual drops or troches) has been available through some telehealth providers and compounding pharmacies. These are not FDA-approved products and are not covered by insurance. With the FDA resolving semaglutide shortage designations and the availability of branded oral options, the regulatory landscape for compounded oral GLP-1s is tightening.
Compounded sublingual semaglutide typically ranges from $150–$400 per month depending on dose and provider. While often less expensive than brand-name options at list price, compounded medications do not have the same manufacturing oversight as FDA-approved products.
The Bottom Line
Oral GLP-1 coverage in 2026 depends primarily on whether your plan covers anti-obesity medications at all — not on whether you're taking a pill or an injection. The Medicare GLP-1 Bridge program, launching July 2026, represents the most significant expansion of oral GLP-1 access for the 65+ population.
For everyone else, check your formulary first. If coverage isn't available, manufacturer savings programs keep self-pay costs between $149–$299 per month for both the Wegovy pill and Foundayo — significantly less than the $1,000+ list prices of injectable alternatives.
Coverage is evolving. Check back with your plan periodically, and talk to your prescriber about which oral GLP-1 gives you the best combination of clinical benefit and financial accessibility.